[200 pages] Report on Global Anticoccidial Drugs Market size was valued at USD 1,137.80 million in 2022 and is estimated to reach a compound annual growth rate (CAGR) of 8.7% over the forecast period 2023-2030.
Coccidiosis is one of the most prevalent parasitic diseases of domesticated animals, and its symptoms include weight loss, mild intermittent to severe diarrhea, feces containing blood or mucus, dehydration, and reduced breeding. Anticoccidial drugs play an essential role in the prevention and treatment of coccidiosis.
Metrics |
Details |
Market CAGR |
8.7% |
Segments Covered |
By Drug Type, By Animal Type, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
The increasing population, rising demand for poultry products, and increasing government support are driving the growth of the market. Innovative animal healthcare products are expected to boost the market over the period forecast.
The increased demand for animal proteins is expected to drive the market growth
Increased demand for animal proteins is expected to boost the market over the period of the forecast. This is owing to the tremendous population growth, which also increased the export of meat, indirectly increasing the demand for veterinary healthcare. For instance, according to the WHO, there is increasing pressure on the livestock sector to meet the rising demand for high-value animal protein. The world's livestock sector is increasing at a huge rate, and the driving force behind this enormous increase is a combination of population growth, rising incomes, and urbanization.
The UN Food and Agriculture Organization has estimated that by 2050, there will be a 73% increase in meat and egg consumption and a 58% increase in dairy consumption over 2011 levels. According to Boehringer Ingelheim by 2050, the global population will reach 9.7 billion people, with a significant increase in the middle class, and substantial growth in emerging markets like Africa and Asia. As a result, the demand for animal protein is expected to increase by 70 percent.
Innovative animal healthcare products are expected to boost the market over the period forecast. For instance, in April 2020 Creative Diagnostics announced the launch of a series of innovative anticoccidial drug analysis services and products for its global clients.
The growing number of regulations and bans on the use of anticoccidial drugs will hamper the growth of the market
However, the growing number of regulations and bans on the use of anticoccidial drugs along with the related costs in developing new drugs increase the need for the development of novel approaches and alternative control strategies for coccidiosis. For instance, the use of alternative treatments such as vaccines, herbal remedies, homeopathy, phytotherapy, and aromatherapy to treat coccidiosis is likely to restrain the growth of the anticoccidial drug market across the world. Resistance has been documented for all those drugs currently employed. Therefore the discovery of novel drugs with unique modes of action is imperative if chemotherapy is to remain the principal means to control this disease.
The ionophore anticoccidials segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The ionophore anticoccidial segment is expected to boost the market. For instance, a significant breakthrough in the prevention of coccidiosis is through feed medication. Ionophores are fermentation products of streptomyces and other fungi species and are the most widely used drugs for coccidiosis prevention due to their broad-spectrum activity against the majority of pathogenic species of coccidia. For many years, ionophores have been the principal choice to control coccidiosis because resistance develops slowly to them and because they do not completely suppress parasite development, thus allowing the development of immunity in the host after first exposure.
Ionophores target the bacteria that produce acetate, giving an advantage to the bacteria that produce propionate. Propionate production is more energetically efficient, so this overall process is what improves the energy status of the animal which leads to greater feed efficiency.
The North American region holds the largest market share of the global anticoccidial drugs market
North America dominates the market for insulin pens and is expected to show a similar trend over the forecast period. This is owing to the availability of Anticoccidial drugs, awareness of the prevention of coccidiosis, safe animal food supply, and high investment in R&D in developing novel products are likely to propel the North American Anticoccidial Drugs market during the forecast period. According to the USDA Economic Research Service, the poultry sector is the fastest-growing meat product market in the US. The size of the poultry segment was around US$ 56 Mn. The raised consumption of meat is expected to accelerate the anticoccidial drug market in North America. For instance, according to the North American meat institute, the meat and poultry industry is the largest segment of U.S. agriculture.
Prevention and control of coccidiosis have usually been done by the combination of different tools, including the correct Animal type of a biosecurity plan, cleaning, and disinfection of the facilities, together with the use of anticoccidial drugs. This factor will drive the growth of the market in the forecast period.
The anticoccidial drugs market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Bayer Animal Healthcare, Boehringer Ingelheim, Ceva Animal Health Inc., Elanco Animal Health (a subsidiary of Eli Lilly), Merck, Merial, Virbac, Zoetis Animal Healthcare, Vetoquinol SA, and others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Anticoccidial Drugs market globally.
Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture, and marketing of innovative healthcare products.
Product Portfolio:
HATCHBACK COCCI III: HATCHPAK COCCI III is a biological tool for the prevention of coccidiosis. It is the only coccidial vaccine in the U.S. to offer genetically stable precocious strains of the three important Eimeria species that affect broilers: E. acervulina, tenella, and E. maxima.
The global anticoccidial drugs market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
$4350
$4350
$4350
$4350
$4350
$4350